Last reviewed · How we verify
NCT06910384
A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)
Phase 2 trial testing STR04 in Amyotrophic Lateral Sclerosis in 1 participant. Terminated before completion.
16 December 2025
Quick facts
| Lead sponsor | New England Cell Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 12 August 2025 |
| Primary completion | 16 December 2025 |
| Estimated completion | 16 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- STR04 — full drug profile →
Conditions studied
- Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Sponsor
New England Cell Therapeutics, Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine.
Panferov E, Dodina M, Reshetnikov V, Ryapolova A, et al · · 2025 · cited 8× · PMID 40565081 · DOI 10.3390/ijms26125617 -
Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.
Mazurek CY, Kaniuk JK, Ahuja CS. · · 2026 · PMID 41809632 · DOI 10.3389/fnmol.2026.1742864 -
Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS.
Loo YS, Yusoh NA, Yap K, Ng CS. · · 2025 · PMID 40858858 · DOI 10.1038/s42003-025-08579-7
Verify or expand the search:
- PubMed search for NCT06910384
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyotrophic Lateral Sclerosis
Currently open trials in the same condition.
- NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
- NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
- NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06910384 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New England Cell Therapeutics, Inc.
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06910384.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing